Danazol versus [d-Trp6]GnRH agonist for the management of infertility due to atypical endometriosis
✍ Scribed by Vasilis A. Tzingounis; Emmanuel Cardamakis
- Book ID
- 104632894
- Publisher
- Springer Netherlands
- Year
- 1996
- Tongue
- English
- Weight
- 309 KB
- Volume
- 3
- Category
- Article
- ISSN
- 1573-3149
No coin nor oath required. For personal study only.
✦ Synopsis
The aim of this study is to assess the impact of atypical endometriosis on fertility as well as the effect of treatment in endometriosis-related infertility. A prospective randomized study comparing the effects of triptorelin (Arvekap, Ipsen) and danazol (Danatrol, Winthrop) was completed recently. The 103 patients (aged 30.9_+4.92, range 21-41) who finished the study were divided into three comparable (infertility duration, age) groups. Group A (n = 37) received danazol (600 mg/day) for 6 months, Group B (n = 32) received triptorelin (3.75 mg) injections, one every 28 days for 6 months, and Group C (n = 34) did not receive any kind of treatment. More pregnancies were observed in Group B (65.62%) compared with Group C (20.58%, p= 0.00012) but not compared with Group A (54.05%, p = 0.05857). The overall monthly fecundity rate in Group B was 0.11, and differences concerning spontaneous abortion rates were not observed. Our results indicate that danazol and triptorelin are equally effective in the treatment of atypical endometriosis-related infertility.